calcium;butanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: calcium;butanoate
• 化学式: C8H14CaO4
• 分子量: 214.27
• InChiKey: FYPVXEILSNEKOO-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -1.31
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  80.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] FOOD SUPPLEMENT AND COMPOSITION COMPRISING CHOLINE BUTYRATE SALT AND/OR BUTYRYLCHOLINE<br/>[FR] COMPLÉMENT ALIMENTAIRE ET COMPOSITION COMPRENANT UN SEL DE BUTYRATE DE CHOLINE ET/OU DE LA BUTYRYLCHOLINE
  申请人：ABERGAVENNY NV

  公开号：WO2017187335A1

  公开（公告）日：2017-11-02

  The present Invention relates to the use of choline butyrate or butyrylcholine in food and in particular in the treatment of Intestinal disorders and in the stimulation of the brain development. Furthermore, the invention provides for a food supplement and a pharmaceutical composition comprising choline butyrate or butyrylcholine, The invention also relates to an animal feed comprising choline butyrate or butyrylcholine or said food supplement.

  本发明涉及在食品中使用胆碱丁酸盐或丁酰胆碱，特别是在治疗肠道疾病和促进大脑发育方面的应用。此外，该发明提供了一种食品补充剂和包含胆碱丁酸盐或丁酰胆碱的药物组合物。该发明还涉及一种含有胆碱丁酸盐或丁酰胆碱或上述食品补充剂的动物饲料。
• ZOFENOPRIL CALCIUM
  申请人：Gore Vinayak G.

  公开号：US20090176860A1

  公开（公告）日：2009-07-09

  The present invention relates to zofenopril calcium form A substantially free of other forms of zofenopril calcium and to zofenopril calcium having a chemical purity of more than 98.5%. The present invention also relates to methods of preparing such zofenopril calcium. It further relates to compositions comprising such zofenopril calcium. Zofenopril calcium, (4S)-1-[(2S)-3-benzoylthio-2-methylpropionyl]-4-(phenylthio)-L-proline calcium salt, has the following structure:

  本发明涉及基本上不含其他形式的左非诺普利钙的左非诺普利钙A型，以及化学纯度超过98.5%的左非诺普利钙，还涉及制备此类左非诺普利钙的方法。此外，还涉及包含此类左非诺普利钙的组合物。左非诺普利钙，即(4S)-1-[(2S)-3-苯甲酰硫基-2-甲基丙酰]-4-(苯硫基)-L-脯氨酸钙盐，具有以下结构：
• PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS
  申请人：Gilead Pharmasset LLC

  公开号：US20150361073A1

  公开（公告）日：2015-12-17

  The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.

  本公开提供了制备一种化合物的方法，该化合物的化学式如下所示：该化合物可用作抗病毒药物。本公开还提供了合成中间体化合物。
• Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
  申请人：Dixit Girish

  公开号：US20110142883A1

  公开（公告）日：2011-06-16

  The present invention relates to stable amorphous co-precipitates of atorvastatin pharmaceutically acceptable salts with pharmaceutically acceptable excipients, method for the preparation, pharmaceutical compositions, and method of treating thereof. Advantageously, the amorphous co-precipitates of atorvastatin pharmaceutically acceptable salts of the present invention have improved physiochemical characteristics that assist in the effective bioavailability

  本发明涉及阿托伐他汀药物可接受盐与药物可接受辅料的稳定非晶共沉淀物、制备方法、制药组合物及其治疗方法。有益的是，本发明的阿托伐他汀药物可接受盐的非晶共沉淀物具有改善的物理化学特性，有助于有效的生物利用度。
• Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
  申请人：Dixit Girish

  公开号：US20100260851A1

  公开（公告）日：2010-10-14

  The present invention provides a novel polymorphic form of atorvastatin calcium, designated as form Al, process for preparation, pharmaceutical compositions, and method of treating thereof. The present invention further provides a process for the preparation of highly pure amorphous atorvastatin calcium using the novel atorvastatin calcium form Al. The present invention also relates to novel amorphous form of atorvastatin tert-butyl ester, chemically known as [R-(R*,R*)]-2-(4-fluorophenyl)-[β],[δ]-dihydroxy -5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl-1H-pyrrole-1-heptanoicacid tert-butyl ester, process for the preparation, and its application for preparing highly pure atorvastatin and its pharmaceutically acceptable salts thereof. The present invention also relates to use of the novel amorphous atorvastatin tert-butyl ester and novel atorvastatin calcium form al for preparing amorphous atorvastatin calcium.

  本发明提供了阿托伐他汀钙的一种新的多晶形式，称为Al型，制备方法、制药组合物和治疗方法。本发明还提供了一种使用新的阿托伐他汀钙Al型制备高纯非晶态阿托伐他汀钙的方法。本发明还涉及阿托伐他汀叔丁基酯的新非晶态形式，化学名称为[R-(R*，R*)]-2-(4-氟苯基)-[β]，[δ]-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基羰氨基)-1H-吡咯烷-1-庚酸叔丁基酯，制备方法及其应用于制备高纯阿托伐他汀及其药用盐。本发明还涉及使用新的非晶态阿托伐他汀叔丁基酯和新的阿托伐他汀钙Al型制备非晶态阿托伐他汀钙。